U.S. Markets close in 4 mins
  • S&P 500

    4,572.06
    -90.79 (-1.95%)
     
  • Dow 30

    35,331.10
    -580.71 (-1.62%)
     
  • Nasdaq

    14,496.31
    -397.45 (-2.67%)
     
  • Russell 2000

    2,105.02
    -57.43 (-2.66%)
     
  • Crude Oil

    85.86
    +2.04 (+2.43%)
     
  • Gold

    1,813.40
    -3.10 (-0.17%)
     
  • Silver

    23.55
    +0.63 (+2.74%)
     
  • EUR/USD

    1.1319
    -0.0092 (-0.8036%)
     
  • 10-Yr Bond

    1.8650
    +0.0930 (+5.25%)
     
  • Vix

    22.72
    +3.53 (+18.39%)
     
  • GBP/USD

    1.3586
    -0.0061 (-0.4443%)
     
  • USD/JPY

    114.6300
    +0.0500 (+0.0436%)
     
  • BTC-USD

    41,669.64
    -510.57 (-1.21%)
     
  • CMC Crypto 200

    992.63
    -16.76 (-1.66%)
     
  • FTSE 100

    7,563.55
    -47.68 (-0.63%)
     
  • Nikkei 225

    28,257.25
    -76.27 (-0.27%)
     

Guardant Health to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor conferences.

  • 10th Annual SVB Leerink Global Healthcare Conference
    Fireside Chat on Friday, February 26th at 1:20 p.m. Pacific Time / 4:20 p.m. Eastern Time

  • Cowen 41st Annual Health Care Conference
    Fireside Chat on Tuesday, March 2nd at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time

Interested parties may access a live and archived webcast of the virtual sessions on the "Investors" section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Revealfor early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Source: Guardant Health, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005765/en/

Contacts

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Anna Czene
press@guardanthealth.com

Courtney Carroll
courtney.carroll@uncappedcommunications.com